Dr Paula Salmikangas, NDA Director for Biopharmaceuticals & ATMPs, will be moderating a 1-hour ‘Working Lunch’ Panel Discussion on “Safety aspects of genetically modified cells” at 1.00-2.00pm on Tuesday, January 23rd 2018 at the Phacilitate Cell & Gene Therapy World conference in Miami.
Paula was previously Chair of the Committee for Advanced Therapies at EMA and has a longstanding experience on ATMPs as a CAT Rapporteur and CMC expert.
The conference brings together industry leaders from the pharma and biotech communities to deliver the ultimate in strategic knowledge exchange and networking.
Reflecting the growing enthusiasm around cell and gene therapy by small and large companies, investors and regulators.
Dr Paula Salmikangas
Advisory Board Director